Navigation Links
Inverness Completes Acquisition of Cholestech
Date:9/12/2007

WALTHAM, Mass., Sept. 12 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (Amex: IMA), a leading manufacturer and marketer of rapid diagnostic products for the consumer and professional markets, announced today the successful completion of its acquisition of Cholestech Corporation (Nasdaq: CTEC). Inverness completed the acquisition through the merger of a wholly owned subsidiary with and into Cholestech, after Cholestech's shareholders approved the deal at a shareholder's meeting today. Cholestech is a leading provider of diagnostic tools and information for immediate risk assessment and therapeutic monitoring of heart disease and inflammatory disorders.

"The acquisition of Cholestech together with our recent and pending acquisitions, provides Inverness with the unique ability to assess cardiac risk, diagnose cardiac conditions and potentially monitor the condition and response to therapy of cardiac patients. The Cholestech LDX System is one of the most established and respected monitoring platforms available to physicians and patients and we believe that this added access to physicians' office laboratories will provide broad benefits for many Inverness and Biosite products," stated Ron Zwanziger, Chairman, President and Chief Executive Officer of Inverness. "We welcome Cholestech and its associates to the Inverness Medical family."

As a result of the merger, Cholestech stockholders received .43642 shares of Inverness common stock for each Cholestech share, resulting in an aggregate issuance of approximately 6,801,946 shares of Inverness common stock. Additionally, each option to purchase shares of Cholestech common stock outstanding prior to the completion of the acquisition has been converted into a right to acquire Inverness shares, at the same exchange ratio of .43642. Cholestech shares will cease trading at the close of business on September 12, 2007 and will be delisted from the Nasdaq.

About Inverness:

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.

For additional information on Inverness Medical Innovations, please visit our website at http://www.invernessmedical.com.

This press release may contain forward-looking statements within the meaning of the federal securities laws. These statements reflect Inverness' current views with respect to future events and are based on management's current assumptions and information currently available. Actual results may differ materially due to numerous factors, including, without limitation, the demand for Cholestech's products, Inverness' ability to integrate Cholestech's business with its existing businesses and to recognize the anticipated benefits of the acquisition, including synergies and accretion, of the transaction; the risks and uncertainties described in Inverness' annual report on Form 10-K/A for the period ended December 31, 2006, and other factors identified from time to time in its periodic filings with the Securities and Exchange Commission. Inverness undertakes no obligation to update any forward- looking statements contained herein.


'/>"/>
SOURCE Inverness Medical Innovations, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. iGATE Completes Phase I Testing Of Meningitis Vaccine
2. Delhi Hospital Completes 100 Liver Transplants
3. Roche Completes Acquisition of BioVeris
4. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
5. Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies
6. NHS financial crisis may lead to roll back of flexi-work scheme and private acquisition
7. Smoking Increases Risk of HIV Acquisition
8. Circassia Announces Acquisition of Organ Transplant Anti-Rejection Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... ... Hamlin Dental Group and Dr. Hamid Reza, dentist in North Hollywood ... of February, patients who visit Hamlin Dental Group will receive a ticket for a ... the Cheesecake Factory. , Tickets are available for routine dental visits and other ...
(Date:2/23/2017)... ... 23, 2017 , ... On April 13, 2017, The ... “Doping in Sport: How the Culture Might Change,” in conjunction with Pepperdine ... will be held at Pepperdine University in Malibu, California. , Sir Philip Craven, ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... uncertainty in clinical trials, today announced that Premier Research, a leading clinical development ... , Clinical trials are becoming increasingly complex, due in part to an array ...
(Date:2/23/2017)... ... 2017 , ... The Center for Autism and Related Disorders ... Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The events ... films in an environment that accommodates their unique needs. , Launched in January, ...
(Date:2/23/2017)... Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... her Smiling Patriot program today with a new Indiegogo campaign . ... care to homeless veterans in the Los Angeles area, either as a participating patient ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 23, 2017 LG Innotek today announced that the company ... As its sterilization performance is 1.5 times higher than the competitor,s ... rays in the range of 200 -- 280nm, allowing it to be ... destroying their DNA. LG Innotek,s product emits UV in the range ... Until ...
(Date:2/23/2017)... 23, 2017 ML Capital Group, Inc. (USOTC: ... Colorado Highlife Tours , a Colorado -based ... with Puration, Inc. (USOTC: PURA) to enter Colorado,s ... The Colorado Highlife Tours acquisition announced today is intended to accelerate ... ...
(Date:2/23/2017)... , Feb. 23, 2017 Provectus Biopharmaceuticals, ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, today ... and Dominic Rodrigues as special advisers to ... Rodrigues will advise the board on financial and corporate ... received an investment commitment of up to $2.5 million ...
Breaking Medicine Technology: